title: On-demand therapy for hereditary angioedema.
abstract: Consensus guidelines on hereditary angioedema (HAE) recommend that all patients have access to on-demand treatment of acute attacks. A recent patientcentric guideline recommended that at least 2 on-demand therapies be available because patients often have heterogeneous responses to different medications. Self-administration of therapeutic agents, or administration under supervision by a health care provider in the home setting, is the preferred treatment approach. Future studies are needed to show the benefits of acute on-demand therapies at improving quality of life and reducing morbidity and mortality in patients with HAE.
authors.affiliation: Allergy Section, Division of Immunology, Department of Internal Medicine, College of Medicine, University of Cincinnati, 3255 Eden Avenue, Suite 350 ML#563, Cincinnati, OH 45267-0563, USA. Electronic address: Jonathan.Bernstein@uc.edu.
authors.forename: Jonathan A
authors.initials: JA
authors.lastname: Bernstein
mesh_terms: D054179:Angioedemas, Hereditary / Q000209:etiology / Q000628:therapy*; D006801:Humans
keywords: Berinert; Ecallantide; Guidelines; Hereditary angioedema; Icatibant; On-demand therapies; Ruconest